Braj News Magazine

DelveInsight’s report titled “Fibromyalgia Pipeline Insight 2023” offers extensive information on more than 12+ companies and over 15+ pipeline drugs in the field of Fibromyalgia research. The Fibromyalgia pipeline report encompasses detailed profiles of the pipeline drugs for Fibromyalgia, including information on Fibromyalgia clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

For the Fibromyalgia emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Fibromyalgia pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Fibromyalgia clinical trial studies conducted for Fibromyalgia, any NDA approvals obtained for Fibromyalgia, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

To explore more information on the latest breakthroughs in the Fibromyalgia Pipeline treatment landscape of the report, click here @ Fibromyalgia Pipeline Outlook

Key Takeaways from the Fibromyalgia Pipeline Report

• DelveInsight’s Fibromyalgia Pipeline analysis depicts a robust space with 12+ active players working to develop 15+ pipeline treatment therapies.
• The leading Fibromyalgia Companies are working in the market include Virios Therapeutics, Tonix Pharmaceuticals, TRYP Therapeutics, UCB, Axsome Therapeutics, Paradise Genomics, AppliedVR, Inc., Aptinyx, Scilex Holding Company, and others
• Promising Fibromyalgia Pipeline Therapies in the various stages of development include Milnacipran 100mg, Duloxetine 60 mg, duloxetine hydrochloride, Saizen, and others
• IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. Virios’ novel FM development candidate, IMC-1, demonstrated exemplary safety and tolerability in the FORTRESS study but did not achieve statistical significance on the pre-specified primary efficacy endpoint of change from baseline in daily self-reported average pain severity scores compared to placebo.
• TNX-102 is a small, rapidly-disintegrating, sublingual product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. TNX-102 is a centrally acting analgesic that helps in relieving pain by improving sleep.

Fibromyalgia Overview

Fibromyalgia (FM) is a syndrome characterized by chronic musculoskeletal pain. The main symptoms of this disease are muscle stiffness, joint stiffness, insomnia, fatigue, mood disorders, cognitive dysfunction, anxiety, depression, general sensitivity and the inability to carry out normal daily activities. FM can also be associated with specific diseases, such as infections, diabetes, rheumatic diseases and psychiatric or neurological disorders.

For further information, refer to the detailed Fibromyalgia Unmet Needs, Fibromyalgia Market Drivers, and Market Barriers, click here for Fibromyalgia Ongoing Clinical Trial Analysis

Fibromyalgia Emerging Drugs Profile

• IMC-1: Virios Therapeutics
• TNX-102: Tonix Pharmaceuticals

Fibromyalgia Pipeline Therapeutics Assessment

There are approx. 12+ Fibromyalgia companies which are developing the therapies for Fibromyalgia. The Fibromyalgia companies which have their Fibromyalgia drug candidates in the most advanced stage, i.e. phase III include, Tonix Pharmaceuticals.

Request a sample and discover the recent advances in Fibromyalgia Ongoing Clinical Trial Analysis and Medications, click here @ Fibromyalgia Treatment Landscape

Fibromyalgia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Fibromyalgia Therapeutics Market include-

Virios Therapeutics, Tonix Pharmaceuticals, TRYP Therapeutics, UCB, Axsome Therapeutics, Paradise Genomics, AppliedVR, Inc., Aptinyx, Scilex Holding Company, and others

Scope of the Fibromyalgia Pipeline Report

• Coverage- Global
• Fibromyalgia Companies- Virios Therapeutics, Tonix Pharmaceuticals, TRYP Therapeutics, UCB, Axsome Therapeutics, Paradise Genomics, AppliedVR, Inc., Aptinyx, Scilex Holding Company, and others
• Fibromyalgia Pipeline Therapies- Milnacipran 100mg, Duloxetine 60 mg, duloxetine hydrochloride, Saizen, and others
• Fibromyalgia Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Fibromyalgia Pipeline, click here @ Fibromyalgia Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Fibromyalgia Executive Summary
3. Fibromyalgia: Overview
4. Fibromyalgia Pipeline Therapeutics
5. Fibromyalgia Therapeutic Assessment
6. Fibromyalgia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. TNX-102: Tonix Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IMC-1: Virios Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Fibromyalgia- Unmet Needs
18. Fibromyalgia- Market Drivers and Barriers
19. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment